The Cellax technology was profiled in a recent issue of SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology's commercialization agent.
Here's an excerpt:
"Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the ...
MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.
Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.
“At MaRS Innovation, the PoP program functions as a kind of internal Dragons' Den,” says Dr. Raphael Hofstein, president ...
Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets.
During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ...
Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots
TORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others.
This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub.
The Crowdmark assessment interface, informed by decades ...
MI start-up ApneaDx Inc. among program's first round of participants
The first three companies selected to participate in the MaRS EXCITE program aim to improve outcomes for breast cancer, sleep apnea and drug-resistant hypertension.
The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.
EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants. (more…)
Four University of Toronto (U of T) professors who have commercialization projects in various stages with MaRS Innovation were named to the university's list of Inventors of the Year.
“The Inventor of the Year Award is meant to recognize inventions that have the potential to improve our quality of life,” said Professor Paul Young, vice-president (research and innovation) and a member of MaRS Innovation's Board of Directors. “The winning inventions represent the very best of innovation at U of T, and on ...
MaRS Innovation's (MI) Lyssa Neel, co-director of the UTEST program and project manager, has been selected to represent MI's ICT start-up companies at the TechWomen Canada program in San Francisco, which runs May 13 to 16, 2013.
The announcement was covered in TechVibes:
TechWomen Canada is run by the Canadian Consulate and is focused on providing Canadian women leaders in the ICT sector an opportunity to expand both professional and business networks in Silicon Valley. (more…)